SCHEMBL21292357

SCHEMBL21292357

O=C(N[C@H]1CC[C@H](CO)CC1)c1nn(C2CCCCO2)c2ccc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 3/20 0.41
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
CNR2 P34972 3/20 0.38
CNR1 P21554 2/20 0.38
IDO1 P14902 1/20 0.37
EPHX2 P34913 1/20 0.37
CDK1 P06493 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
RAB9A P51151 3/20 0.37
TP53 P04637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21292360 1.00 PDE7A (0.41) PDE7ARXRARXRBRXRGCNR2
SCHEMBL21292263 0.89 DYRK1A (0.41) PDE7ACNR2CNR1IDO1EPHX2
SCHEMBL21292262 0.89 DYRK1A (0.41) PDE7ACNR2CNR1IDO1EPHX2
SCHEMBL21292351 0.87 TRPV1 (0.37) RXRARXRBRXRGCNR2CNR1
SCHEMBL21292352 0.87 TRPV1 (0.37) RXRARXRBRXRGCNR2CNR1
SCHEMBL21292340 0.81 HTR3A (0.37) RXRARXRBRXRGCNR2CNR1
SCHEMBL6507201 0.80 RXRA (0.41) RXRARXRBRXRGCNR2IDO1
SCHEMBL6502144 0.79 RXRA (0.39) RXRARXRBRXRGCNR2CNR1
SCHEMBL6502931 0.78 ELANE (0.51) RXRARXRBRXRGCNR2CDK1
SCHEMBL29593200 0.78 ELANE (0.51) RXRARXRBRXRGCNR2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
EP-3755696-B1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF BIOSPLICE THERAPEUTICS INC (US) 2023-04-05 EP disclosed
US-20220402921-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2022-12-22 US disclosed
US-10934297-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2021-03-02 US disclosed
US-20190263821-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934297-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, DYRK3 PDE7A 2537/4885RXRA 1271/4885RXRB 2194/4885
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, DYRK3 PDE7A 2537/4885RXRA 1271/4885RXRB 2194/4885
US-20220402921-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, DYRK3 PDE7A 2537/4885RXRA 1271/4885RXRB 2194/4885
US-20190263821-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, DYRK3 PDE7A 2537/4885RXRA 1271/4885RXRB 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.